Holger Fröhlich1, Sabyasachi Patjoshi1, Kristina Yeghiazaryan2,3,4, Christina Kehrer3,4,5, Walther Kuhn3,4,5, Olga Golubnitschaja2,3,4. 1. 1Bonn-Aachen International Centre for IT, Friedrich-Wilhelms-Universität Bonn, Bonn, Germany. 2. 2Radiological Clinic, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany. 3. 3Breast Cancer Research Centre, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany. 4. 4Centre for Integrated Oncology, Cologne-Bonn, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany. 5. 5Centre for Obstetrics and Gynaecology, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany.
Abstract
BACKGROUND: The breast cancer (BC) epidemic is a multifactorial disease attributed to the early twenty-first century: about two million of new cases and half a million deaths are registered annually worldwide. New trends are emerging now: on the one hand, with respect to the geographical BC prevalence and, on the other hand, with respect to the age distribution. Recent statistics demonstrate that young populations are getting more and more affected by BC in both Eastern and Western countries. Therefore, the old rule "the older the age, the higher the BC risk" is getting relativised now. Accumulated evidence shows that young premenopausal women deal with particularly unpredictable subtypes of BC such as triple-negative BC, have lower survival rates and respond less to conventional chemotherapy compared to the majority of postmenopausal BC. WORKING HYPOTHESIS: Here we hypothesised that a multi-level diagnostic approach may lead to the identification of a molecular signature highly specific for the premenopausal BC. A multi-omic approach using machine learning was considered as a potent tool for stratifying patients with benign breast alterations into well-defined risk groups, namely individuals at high versus low risk for breast cancer development. RESULTS AND CONCLUSIONS: The study resulted in identifying multi-omic signature specific for the premenopausal BC that can be used for stratifying patients with benign breast alterations. Our predictive model is capable of discriminating individually between high and low BC-risk with high confidence (>90%) and considered of potential clinical utility. Novel risk assessment approaches and advanced screening programmes-as the long-term target of this project-are of particular importance for predictive, preventive and personalised medicine as the medicine of the future, due to the expected health benefits for young subpopulations and the healthcare system as a whole.
BACKGROUND: The breast cancer (BC) epidemic is a multifactorial disease attributed to the early twenty-first century: about two million of new cases and half a million deaths are registered annually worldwide. New trends are emerging now: on the one hand, with respect to the geographical BC prevalence and, on the other hand, with respect to the age distribution. Recent statistics demonstrate that young populations are getting more and more affected by BC in both Eastern and Western countries. Therefore, the old rule "the older the age, the higher the BC risk" is getting relativised now. Accumulated evidence shows that young premenopausal women deal with particularly unpredictable subtypes of BC such as triple-negative BC, have lower survival rates and respond less to conventional chemotherapy compared to the majority of postmenopausal BC. WORKING HYPOTHESIS: Here we hypothesised that a multi-level diagnostic approach may lead to the identification of a molecular signature highly specific for the premenopausal BC. A multi-omic approach using machine learning was considered as a potent tool for stratifying patients with benign breast alterations into well-defined risk groups, namely individuals at high versus low risk for breast cancer development. RESULTS AND CONCLUSIONS: The study resulted in identifying multi-omic signature specific for the premenopausal BC that can be used for stratifying patients with benign breast alterations. Our predictive model is capable of discriminating individually between high and low BC-risk with high confidence (>90%) and considered of potential clinical utility. Novel risk assessment approaches and advanced screening programmes-as the long-term target of this project-are of particular importance for predictive, preventive and personalised medicine as the medicine of the future, due to the expected health benefits for young subpopulations and the healthcare system as a whole.
Entities:
Keywords:
Bioinformatics; Biomarker panel; Breast cancer; Laboratory medicine; Machine learning; Menopause; Multi-level diagnostics; Patient stratification; Predictive preventive personalised medicine
Authors: D F Merlo; M Ceppi; R Filiberti; V Bocchini; A Znaor; M Gamulin; M Primic-Žakelj; P Bruzzi; C Bouchardy; A Fucic Journal: Breast Cancer Res Treat Date: 2012-03-29 Impact factor: 4.872
Authors: Natalie J Engmann; Marzieh K Golmakani; Diana L Miglioretti; Brian L Sprague; Karla Kerlikowske Journal: JAMA Oncol Date: 2017-09-01 Impact factor: 31.777
Authors: C Bouchardy; G Fioretta; H M Verkooijen; G Vlastos; P Schaefer; J-F Delaloye; I Neyroud-Caspar; S Balmer Majno; Y Wespi; M Forni; P Chappuis; A-P Sappino; E Rapiti Journal: Br J Cancer Date: 2007-05-29 Impact factor: 7.640
Authors: Michelle N Harvie; Andrew H Sims; Mary Pegington; Katherine Spence; Adam Mitchell; Andrew A Vaughan; J William Allwood; Yun Xu; Nicolas J W Rattray; Royston Goodacre; D Gareth R Evans; Ellen Mitchell; Debbie McMullen; Robert B Clarke; Anthony Howell Journal: Breast Cancer Res Date: 2016-05-28 Impact factor: 6.466
Authors: Sona Uramova; Peter Kubatka; Zuzana Dankova; Andrea Kapinova; Barbora Zolakova; Marek Samec; Pavol Zubor; Anthony Zulli; Vanda Valentova; Taeg Kyu Kwon; Peter Solar; Martin Kello; Karol Kajo; Dietrich Busselberg; Martin Pec; Jan Danko Journal: EPMA J Date: 2018-11-12 Impact factor: 6.543
Authors: Alena Liskova; Patrik Stefanicka; Marek Samec; Karel Smejkal; Pavol Zubor; Tibor Bielik; Kristina Biskupska-Bodova; Taeg Kyu Kwon; Jan Danko; Dietrich Büsselberg; Mariusz Adamek; Luis Rodrigo; Peter Kruzliak; Aleksandr Shleikin; Peter Kubatka Journal: Clin Exp Med Date: 2020-02-03 Impact factor: 3.984
Authors: A Kapinova; P Kubatka; O Golubnitschaja; M Kello; P Zubor; P Solar; M Pec Journal: Environ Health Prev Med Date: 2018-08-09 Impact factor: 3.674
Authors: Pavol Zubor; Peter Kubatka; Karol Kajo; Zuzana Dankova; Hubert Polacek; Tibor Bielik; Erik Kudela; Marek Samec; Alena Liskova; Dominika Vlcakova; Tatiana Kulkovska; Igor Stastny; Veronika Holubekova; Jan Bujnak; Zuzana Laucekova; Dietrich Büsselberg; Mariusz Adamek; Walther Kuhn; Jan Danko; Olga Golubnitschaja Journal: Int J Mol Sci Date: 2019-06-13 Impact factor: 5.923
Authors: Karin Jasek; Peter Kubatka; Marek Samec; Alena Liskova; Karel Smejkal; Desanka Vybohova; Ondrej Bugos; Kristina Biskupska-Bodova; Tibor Bielik; Pavol Zubor; Jan Danko; Marian Adamkov; Taeg Kyu Kwon; Dietrich Büsselberg Journal: Biomolecules Date: 2019-07-18